SPOTLIGHT -
How Do We Treat Children with Systemic Eczema Therapies?
With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.
Katie Falloon, MD: Finding Biomarkers for Pouch Inflammation
Falloon presented new data at ACG 2022 on identifying biomarkers for pouch inflammation.
The Future of Tailored Alopecia Treatment
In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.
Advances to Alopecia Areata Treatment and Diagnostics
Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.
Baricitinib Has Reinvigorated Patients with Alopecia Areata
Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.
Why Ruxolitinib May Alter Atopic Dermatitis Care Options
The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.
How Likely Is A Vaccine for Acne?
Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.
What Does an Acne Patient Want From Clinical Care?
With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.
How Narrow-Spectrum Antibiotics Shifted Acne Treatment Strategy
Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.
What Does It Take to Initiate JAK Inhibitors for Psoriasis?
Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.
Karan Lal, DO: Preferred Treatments for Adult Plaque Psoriasis Patients
A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.
The Implications of Deucravacitinib's Approval for Psoriasis
A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.
JAK Inhibitors Ended the Novel Atopic Dermatitis Treatment "Drought"
Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.
The Emerging Oral & Topical Agents for Psoriasis
Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.
Sanjiv Chopra, MD: Future Advances in Artificial Intelligence, Gut Bacteria Research, CRISPR Technology
Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.
Sanjiv Chopra, MD: What Are the 5 Most Impactful Medical Science Advances for the Future?
Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.
Prevent, Treat Diabetes by Understanding the Basics of Obesity Management
As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.
Apremilast Also Addresses Manifestations of Psoriatic Arthritis
Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.
Tirzepatide vs. Semaglutide: Tina Thethi, MD, Details the Differences Seen in Diabetes, Obesity
The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.
Tina Thethi, MD: GLP-1 RA Benefits Extend Beyond Diabetes, Obesity
"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.
Veronica Anwuri, MD: Benefits of Apremilast Treatment for Adult Plaque Psoriasis
An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.
Frank Lavernia, MD, Discusses How Obesity Treatment is Changing
Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.
Frank Lavernia, MD, Talks About the Reduced Risk of MACE With GLP-1 RAs
Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.
Robert Kushner, MD: Treatment Options to Address Diabetes, Obesity
In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.
Charles Vega, MD: Colorectal Cancer Screenings, Preventative Services
A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.
Robert Kushner, MD: Addressing the Importance of Lifestyle With Patients Who Have Diabetes, Obesity
Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.
Charles Vega, MD: Atrial Fibrillation, Risk Factors for Autosomal Dominant Polycystic Kidney Disease
An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.
Michael Angarone, DO: Virus Outbreaks, Treating Hepatitis C in Developing Countries
A discussion with Dr. Angarone regarding his presentation at Pri-Med Midwest, exploring the topic of treating infectious disease in developing countries.
Charles Vega, MD: Common Urgent Care Presentations, Acute Pain Concerns
A discussion regarding highlights from Dr. Charles Vega’s presentation on common urgent care presentations and concerns regarding acute pain.
Robert Kushner, MD: Why Aren't Weight Loss Agents Reaching Patients With Obesity?
"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.
